

**Supplementary Table 1.** The schedule of enrolment, interventions, and assessments of this trial

		STUDY PERIOD							
	Enrolment	Allocation	Post-allocation						Close-out
Windows:	October -2023	2023	Day 0	4W ± 3D	12 W ± 7D	24W ± 7D	36W ± 7D	48 W ± 7D	End-2025
ENROLMENT:									
Eligibility screen	×								
Informed consent	×								
Allocation		×							
INTERVENTIONS:									
[0.01 % atropine eye drops]			×	×	×	×	×	×	
[placebo eye drops]			×	×	×	×	×	×	
ASSESSMENTS:									
[The baseline variables]	×	×							
[The primary outcome]			×	×	×	×	×	×	
[The secondary outcome]			×	×	×	×	×	×	
[Safety evaluation]			×	×	×	×	×	×	

W: Weeks; D: Days